Immune Checkpoint-Regulatable Hydrogel-Immobilized Nanotherapeutics for Post-Surgical Treatment of Osteosarcoma
Da-Wang Zhao,Zhiliang Gao,Meng Si,Rui Hu,Xue Ma,Kaiwen Liu,Yixiang Zhao,Qiting He,Xiangzhen Kong,Chunwang Jia,Haoxin Zhai,Yuanqiang Zhang,Lei Cheng,Jiwei Cui,He-Cheng Ma
DOI: https://doi.org/10.1016/j.cej.2024.155072
IF: 15.1
2024-01-01
Chemical Engineering Journal
Abstract:Osteosarcoma recurrence following surgical resection is notoriously prevalent and resistant to chemotherapy (i. e., doxorubicin, DOX) due to its intricate immunosuppressive tumor microenvironment, which remains one of the most life-threatening tumors. In this study, we report the fabrication of an in-situ injectable hydrogelimmobilized nanotherapeutics, tailored to stimulate tumoricidal immunity, thus mitigate both localized osteosarcoma recurrence and the propagation of metastatic tumors subsequent to surgical intervention. Zeolitic imidazolate framework-8 nanoparticles (ZIF NPs), encapsulating a chemotherapeutic agent (i.e., DOX) and immunotherapeutic agents (i.e., alpha PDL1 and alpha CD47), are loaded in fibrin hydrogels. These bioengineered constructs are judiciously deployed at surgical sites to orchestrate chemo-immunotherapeutic interventions, effectuated through the controlled release of doxorubicin and the initiation of T cell-mediated immune responses. DOX has the capability to eradicate tumor cells and initiate immunogenic cell death. Notably, alpha PDL1 engenders the circumvention of PDL1-mediated resistance and dominates metastatic tumor expansion, thereby exerting a pivotal role in the context of systemic immunosuppression. alpha CD47 blocks the 'don't eat me' signaling axis intrinsic to cancer cells, thereby potentiating their phagocytosis by macrophages. This orchestrated blockade synergistically activates the host immune milieu, thereby repressing tumor recurrence and curtailing the growth of metastatic lesions post-surgical resection in the subcutaneous tumor model (lateral and bilateral) and tibial tumor model (orthotopic and metastatic), respectively. Additionally, zinc ions from the degradation of ZIF NPs acts as the stimulator of interferon genes (STING) agonists to enhance the immunotherapeutic activity against distal and metastatic tumors. The reported immune checkpoint-regulatable cancer immunotherapy activates the host innate and adaptive immune systems, which shows promising for the treatment of osteosarcoma patients.